In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2
Explore this issueNovember 2016
Also by this Author
“The new list of treatment recommendations provides a way for clinicians to keep up with the literature in a field that rapidly evolves,” says Arthur Kavanaugh, MD, a coauthor of the recommendations, and professor of medicine in the Division of Rheumatology, Allergy and Immunology at the University of California–San Diego, La Jolla, Calif. “The recommendations also reflect a growing appreciation of other aspects of the disease, such as the importance of comorbidities, which previous recommendations did not address,” he adds.
Along with including the importance and treatment of comorbidities associated with PsA, the new recommendations include three new classes of drugs that have come to the market since the 2009 recommendations. These include interleukin 12- and 23-blocking drugs, an interleukin 17-blocking drug and a small-molecule drug that inhibits phosphodiesterase 4.
“The old recommendations had the tumor necrosis factor inhibitors as the only biologics,” says Atul Deodhar, MD, professor of medicine, and medical director of the Rheumatology Clinic, as well as Immunotherapy Infusion Center, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Ore. “Rheumatologists may not be aware of the appropriate place in the treatment plan for these new class of drugs, so these recommendations are needed to help guide them on how they can be used and when they can be used.”
The 2015 updated recommendations were developed by a panel of GRAPPA rheumatologists, dermatologists and patients with PsA, which reviewed the current literature on treatment of key domains of PsA, including arthritis, spondylitis, enthesitis, dactylitis, skin disease and nail disease. New to this update was the inclusion of a review to identify pertinent comorbidities associated with PsA and their effect on treatment.